echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Rheumatology: Low-dose rituximab is effective in refractory idiopathic inflammatory myopathy

    Rheumatology: Low-dose rituximab is effective in refractory idiopathic inflammatory myopathy

    • Last Update: 2022-08-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    OBJECTIVE: The early use of rituximab (RTX) in refractory idiopathic inflammatory myopathy (IIM) has not been well studie.


    Methods: Registration-based observational data from patients with IIM receiving rituximab from 2018 to 2021 were include.


    Results: A total of 42 patients (F:M=29:13) were included, with an average age (standard deviation) of 35 (±15) year.


    Most patients received rituximab for refractory myositis after a median (IQR) duration of 8 (4, 18) month.


    Improvements in manual muscle test (MMT-8) scores, PGA (Physician's Global Assessment), PtGA (Patient's Global Assessment), median steroid dose compared to baseline after 6 and 12 months of RTX ( p<01 for all items.


    Changes in MMT-8, PGA, and PtGA scores were significantly different for both RTX dose regimens at 6 and 12 months from baselin.


    Three patients in the cohort developed severe lower respiratory tract infections requiring hospitalizatio.


    CONCLUSIONS: In this registry-based cohort study of refractory IIM, rituximab improved IMACS core-group measures with steroid-preserving efficacy at 6 and 12 month.


    Source:

    Janardana R, Amin SN, Rajasekhar L, et a.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.